Overview We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to trick the bodys immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designe...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134950 | EDGAR | 90K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047921 | EDGAR | — |
| 2024-10-07 | 2024-06-30 | 0000950170-24-113321 | EDGAR | — |
| 2023-09-18 | 2023-06-30 | 0000950170-23-048588 | EDGAR | — |
| 2022-09-27 | 2022-06-30 | 0000950170-22-018865 | EDGAR | — |
| 2021-09-28 | 2021-06-30 | 0001564590-21-049235 | EDGAR | — |
| 2020-09-18 | 2020-06-30 | 0001564590-20-044019 | EDGAR | — |
| 2019-09-09 | 2019-06-30 | 0001213900-19-017497 | EDGAR | — |
| 2018-09-24 | 2018-06-30 | 0001213900-18-012876 | EDGAR | — |
| 2017-09-27 | 2017-06-30 | 0001213900-17-010055 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281539 | EDGAR | 26K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108972 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072745 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127199 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059694 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0000950170-24-015204 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062915 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020854 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0000950170-23-002805 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023988 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0000950170-22-009809 | EDGAR | — |
| 2022-02-11 | 2021-12-31 | 0001564590-22-004688 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001193125-26-135766 | EDGAR | 1K words |
| 2026-01-30 | 0001193125-26-031742 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314302 | EDGAR | — |
| 2025-12-05 | 0001193125-25-309853 | EDGAR | — |
| 2025-11-25 | 0001193125-25-294581 | EDGAR | — |
| 2025-11-18 | 0001193125-25-286419 | EDGAR | — |
| 2025-11-14 | 0001193125-25-281522 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263523 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262562 | EDGAR | — |
| 2025-10-31 | 0001193125-25-260924 | EDGAR | — |
331 total filings indexed. 299 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001498382 |
| Ticker | HURA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.tuhurabio.com |
| Listed | 2024-10-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report